A detailed history of Exodus Point Capital Management, LP transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Exodus Point Capital Management, LP holds 151,100 shares of VKTX stock, worth $6.4 Million. This represents 0.06% of its overall portfolio holdings.

Number of Shares
151,100
Previous 274,500 44.95%
Holding current value
$6.4 Million
Previous $14.5 Million 34.12%
% of portfolio
0.06%
Previous 0.1%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$49.84 - $70.47 $10.5 Million - $14.8 Million
210,229 Added 397.18%
263,159 $16.7 Million
Q2 2024

Aug 13, 2024

BUY
$47.39 - $80.2 $1.84 Million - $3.11 Million
38,835 Added 275.52%
52,930 $2.81 Million
Q1 2024

May 14, 2024

BUY
$17.4 - $94.5 $245,252 - $1.33 Million
14,095 New
14,095 $1.16 Million
Q3 2022

Nov 10, 2022

BUY
$2.55 - $3.89 $16,605 - $25,331
6,512 Added 26.86%
30,753 $84,000
Q2 2022

Aug 19, 2022

BUY
$2.11 - $3.15 $51,148 - $76,359
24,241 New
24,241 $70,000
Q4 2021

Feb 11, 2022

SELL
$4.6 - $6.72 $112,262 - $164,001
-24,405 Closed
0 $0
Q3 2021

Nov 15, 2021

SELL
$5.58 - $7.04 $285,891 - $360,694
-51,235 Reduced 67.74%
24,405 $153,000
Q2 2021

Aug 16, 2021

BUY
$5.19 - $6.73 $84,892 - $110,082
16,357 Added 27.59%
75,640 $453,000
Q1 2021

May 17, 2021

BUY
$5.74 - $9.67 $340,284 - $573,266
59,283 New
59,283 $375,000
Q3 2020

Nov 16, 2020

SELL
$5.73 - $8.11 $151,667 - $214,663
-26,469 Closed
0 $0
Q2 2020

Aug 14, 2020

BUY
$4.35 - $8.08 $115,140 - $213,869
26,469 New
26,469 $191,000
Q1 2020

May 15, 2020

SELL
$3.45 - $7.95 $69,351 - $159,810
-20,102 Closed
0 $0
Q4 2019

Feb 14, 2020

SELL
$6.38 - $8.73 $98,902 - $135,332
-15,502 Reduced 43.54%
20,102 $161,000
Q3 2019

Nov 14, 2019

BUY
$6.55 - $8.6 $117,677 - $154,507
17,966 Added 101.86%
35,604 $245,000
Q2 2019

Aug 14, 2019

BUY
$7.67 - $10.63 $135,283 - $187,491
17,638 New
17,638 $146,000

Others Institutions Holding VKTX

About Viking Therapeutics, Inc.


  • Ticker VKTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,688,496
  • Market Cap $3.25B
  • Description
  • Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...
More about VKTX
Track This Portfolio

Track Exodus Point Capital Management, LP Portfolio

Follow Exodus Point Capital Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Exodus Point Capital Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Exodus Point Capital Management, LP with notifications on news.